Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genzyme, a Sanofi Company
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Females of child bearing potential must agree to abstain from sexual activity or to use a medically approved contraceptive measure/regimen during and for 3 months after the treatment period or be surgically sterile. Males must agree to abstain from sexual activity or agree to utilize a medically approved contraception method during treatment and for 3 months after the treatment period or be surgically sterile.
Diagnosis of CLL or SLL, relapsed from at least one prior therapy.
CLL/SLL cells expressing CD20 documented during screening.
Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.
Life expectancy of at least 12 weeks.
Serum creatinine ≤2.0 mg/dL.
Total bilirubin ≤2.0 mg/dL.
ALT (alanine aminotransferase) and AST (aspartate aminotransaminase) ≤2 times the upper limit of normal (ULN); for patients with liver involvement of CLL/SLL disease, this limit is increased to ≤5 times the ULN.
At the time of enrollment, patients must be \>4 weeks since major surgery, radiotherapy, chemotherapy (\>6 weeks for some chemotherapies), immunotherapy, biotherapy/targeted or investigational therapies and recovered from the toxicity of prior treatment to ≤ grade 1.
You may not be if
White Blood Cells (WBC) \>250 x 10\^9 cells/L.
Disease refractory to rituximab therapy- defined as a failure to respond to prior rituximab-containing regimen.
Women who are breastfeeding.
Active viral hepatitis.
Active infection or treatment with antimicrobial or antiviral therapy within 1 week of enrollment with the exception of prophylactic therapy.
History of prior allergic reaction to plerixafor or rituximab.
Significant lung disease.
Serious cardiac disease such as a history of sustained ventricular arrhythmia, uncontrolled and serious congestive heart failure (CHF), angina, acute coronary syndrome, or myocardial infarction within 6 months of enrollment or other significant medical or psychosocial conditions that warrants exclusion.
Clareo Health | Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
